BC Extra | Nov 26, 2019
Company News

After mid-decade makeover, Medicines Co. accepts Novartis' $9.7B bid on eve of inclisiran submission

Novartis’ $9.7 billion acquisition of The Medicines Co. gives the pharma an RNAi-based cholesterol-lowering therapy that could capture a larger share of the cardiovascular disease market than approved PCSK9 inhibitors have been able to grab....
BC Week In Review | Dec 1, 2017
Company News

Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline. Medicines Co. will receive $270 million up front,...
BC Extra | Nov 30, 2017
Company News

Melinta acquires Medicines Co.'s infectious disease unit

Melinta Therapeutics Inc. (NASDAQ:MLNT) will acquire the infectious disease business unit of The Medicines Co. (NASDAQ:MDCO), including marketed drugs Vabomere meropenem/vaborbactam, Orbactiv oritavancin and Minocin IV minocycline. Medicines Co. will receive $270 million up front,...
BC Week In Review | Oct 27, 2017
Company News

Medicines Co. to cut workforce, focus on inclisiran

In its 3Q17 earnings announcement, The Medicines Co. (NASDAQ:MDCO) said it would reduce headcount to fewer than 60 employees to focus on developing inclisiran (PCSK9si). On Oct. 25, the company said it plans to start...
BC Extra | Oct 25, 2017
Company News

Medicines Co. to cut workforce, focus on inclisiran

In its 3Q17 earnings announcement, The Medicines Co. (NASDAQ:MDCO) said it would reduce headcount to fewer than 60 employees to focus on developing inclisiran ( PCSK9si ). Next week, the company plans to start a Phase...
BC Extra | May 10, 2016
Company News

Medicines Co. selling some CV assets to Chiesi

The Medicines Co. (NASDAQ:MDCO) is selling its non-core cardiovascular assets to Chiesi Farmaceutici S.p.A. (Parma, Italy). The deal includes Cleviprex clevidipine , Kengreal cangrelor and the company's rights to ready to use argatroban . It does not...
BioCentury | Apr 4, 2016
Finance

1Q approvals

1Q approvals Company Approval Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Japan approves Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D) Amgen Inc. (NASDAQ:AMGN) Japan approves Repatha evolocumab to treat familial hypercholesterolemia or hypercholesterolemia in patients...
BC Week In Review | Mar 21, 2016
Clinical News

Kangio bivalirudin regulatory update

FDA issued a complete response letter to Eagle for an NDA for anticoagulant Kangio bivalirudin, a ready-to-use formulation of Angiomax bivalirudin from The Medicines Co. (NASDAQ:MDCO, Parsippany, N.J). The agency is requesting “further characterization of...
BC Extra | Mar 19, 2016
Company News

Eagle slides after FDA rejects anticoagulant Kangio

Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) sank $10.18 (19%) to $43.50 on Friday after FDA issued a complete response letter for an NDA for anticoagulant Kangio bivalirudin , a ready-to-use formulation of Angiomax bivalirudin from The Medicines Co....
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
Items per page:
1 - 10 of 349